Advancing a novel product pipeline of neurology therapies
View Product PipelineAbout
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions.
Xenon is advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.
Read MoreNews
Xenon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 26, 2020
Xenon Reports 2019 Financial Results and Provides Corporate Update
March 9, 2020
Xenon to Host Conference Call and Webcast to Discuss 2019 Financial Results and Provide Corporate Update
March 2, 2020
Xenon Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
February 14, 2020
Xenon Announces Closing of its $60.0 Million Public Offering of Common Shares
January 27, 2020
Xenon Announces Pricing of $60.0 Million Public Offering of Common Shares
January 22, 2020
Product Pipeline
* A physician-led, Phase 2 proof-of-concept study is ongoing to examine XEN007 as an adjunctive treatment in pediatric patients diagnosed with treatment-resistant childhood absence epilepsy (CAE).
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
